UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024313
Receipt number R000027879
Scientific Title Intratympanic steroid for Bell's palsy. Single-centre randomized controlled trial.
Date of disclosure of the study information 2016/10/07
Last modified on 2020/01/10 16:16:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Intratympanic steroid for Bell's palsy. Single-centre randomized controlled trial.

Acronym

Intratympanic steroid for Bell's palsy

Scientific Title

Intratympanic steroid for Bell's palsy. Single-centre randomized controlled trial.

Scientific Title:Acronym

Intratympanic steroid for Bell's palsy

Region

Japan


Condition

Condition

Bell's palsy

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess intratypmanic steroid injection for Bell's palsy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Non-recovery rate(House-Brackmann grade 3 or more) at 6 month after disease onset.
We define recovery as House-Brackmann grade 1-2.
Primary outcome will be measured by blinded assesser.

Key secondary outcomes

Non-recovery rate at last follow up (6 to 12 month after disease onset)
Tympanic membrane perforation and any complications during intratympanic injection (e.g. vertigo, vomiting, and vasovagal syncope)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Control group: Conventional treatment (60 mg/day for 5 days, then taper) and anti-viral drug (Valacyclovir 3000mg/day for 5days)

Interventions/Control_2

Intervention group: Intratympanic steroid (0.5 ml Dexamethasone once or twice per week for 2weeks) add to conventional treatment

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

200 years-old >

Gender

Male and Female

Key inclusion criteria

Within 1 weeks after disease onset
Severe facial palsy (Yanagihara facial grade 12 or less)

Key exclusion criteria

Pregnancy, breast-Feeding.
dementia and difficult to enroll trial.

Target sample size

108


Research contact person

Name of lead principal investigator

1st name Takashi
Middle name
Last name Fujiwara

Organization

Kurashiki Central Hospital

Division name

Otolaryngology

Zip code

710-8602

Address

1-1-1 Miwa, Kurashiki City, Okayama Prefecture

TEL

086-422-0210

Email

t.fujiwarabi@gmail.com


Public contact

Name of contact person

1st name Yuki
Middle name
Last name Nyuko

Organization

Clinical Research Center Kurashiki Central Hospital

Division name

Clinical Research Center Kurashiki Central Hospital

Zip code

710-8602

Address

1-1-1 Miwa, Kurashiki City, Okayama Prefecture

TEL

086-422-0210

Homepage URL


Email

tf14817@kchnet.or.jp


Sponsor or person

Institute

Kurashiki Central Hospital

Institute

Department

Personal name



Funding Source

Organization

No funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Kurashiki Central Hospital

Address

Miwa 1-1-1, Kurashiki City, Okayama, Japan

Tel

+81-86-422-0210

Email

tf14817@kchnet.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

倉敷中央病院


Other administrative information

Date of disclosure of the study information

2016 Year 10 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 08 Month 17 Day

Date of IRB

2016 Year 10 Month 19 Day

Anticipated trial start date

2016 Year 11 Month 01 Day

Last follow-up date

2018 Year 09 Month 08 Day

Date of closure to data entry

2018 Year 12 Month 31 Day

Date trial data considered complete

2018 Year 12 Month 31 Day

Date analysis concluded

2018 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 10 Month 06 Day

Last modified on

2020 Year 01 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027879


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name